Clinical trials: Cervical Neoplasms
Cervical Cancer
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
The purpose of this study is to find out whether patients with cervical cancer treated with PET-guided Bone Marrow Sparing IMRT have less side effects with equal cancer control compared to standard radiation techniques (IMRT).
- Trial name
- NCT01554397
- Testing
- PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT), Cisplatin, IMRT
- Where
- 7 sites in United States, China and 4 more
- Volunteers
- 101 people
- Sponsor
- University of California, San Diego
Thyroid Cancer
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily…
- Trial name
- NCT02702388
- Testing
- Lenvatinib
- Where
- 101 sites in United States, Australia and 14 more
- Volunteers
- 241 people
- Sponsor
- Eisai Inc.
Head and Neck, Squamous Cell Cancer
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well.
- Trial name
- NCT00661427
- Testing
- cetuximab
- Where
- 17 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
The results of previous studies suggest further development of [18F]EF5 as a PET tracer for imaging hypoxia. This is a non-randomized prospective study to obtain information on reproducibility of [18F]EF5 intratumor distribution…
- Trial name
- NCT01774760
- Testing
- 18F-EF5, Pretreatment PET/CT-scan (performed two times)
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- Turku University Hospital
Head and Neck Cancer
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00089297
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Esophageal Neoplasms
A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer
This descriptive cross sectional study aims to directly compare the diagnostic capability of the probed-based confocal laser endomicroscopy (pCLE) and the magnifying narrow band imaging (M-NBI) in the Lugol's voiding lesions.
- Trial name
- NCT02182804
- Testing
- Olympus, Cellvizio
- Volunteers
- 44 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00820248
- Testing
- panitumumab, cisplatin, 3-dimensional conformal radiation therapy
- Where
- 19 sites in Canada
- Volunteers
- 320 people
- Sponsor
- NCIC Clinical Trials Group
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
High Risk Cervical Cancer, Advanced Cervical Cancer
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need.
- Trial name
- AIM2CERV (NCT02853604)
- Testing
- ADXS11-001
- Where
- 117 sites in United States, Argentina and 12 more
- Volunteers
- 110 people
- Sponsor
- Advaxis, Inc.
Difficult Intubation
Evaluation of Video Laryngoscopy in Patients With Head and Neck Pathology
Patients who undergo general anesthesia for surgical procedures frequently need to have a breathing tube placed ("tracheal intubation") for the duration of the procedure.
- Trial name
- NCT03265938
- Testing
- Indirect Laryngoscopy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
This is a multicenter placebo-controlled clinical trial to assess the effects of a topically applied gel on precancerous oral epithelial lesions.
- Trial name
- NCT01192204
- Testing
- 10% FBR containing bioadhesive gel
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ohio State University
Oncologic Complications, Quality of Life
Nutrition and Pharmacological Algorithm for Oncology Patients Study
Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease…
- Conditions
- Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer
- Trial name
- NCT04155008
- Testing
- Dexamethasone, Dronabinol, Mirtazapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Oral Mucositis
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
- Trial name
- NCT02013050
- Testing
- SGX942
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Soligenix
Post-operative Pneumonia, Lung Cancer
Prevention of Post-operative Pneumonia (POPP)
Postoperative pneumonia is a major complication in patients undergoing thoracic surgery. It leads to considerable morbidity and contributes to perioperative morbidity.
- Conditions
- Post-operative Pneumonia, Lung Cancer, Esophageal Cancer
- Trial name
- POPP (NCT01446874)
- Testing
- 0.12% chlorhexidine solution
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Esophageal Cancer
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
The interaction of epidermal growth factor receptor (EGFR) inhibitory agents such as cetuximab combined with radiation shows promising results.
- Trial name
- NCT00319735
- Testing
- Radiation Therapy, Surgery, Tissue Sample
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Nasser Hanna, M.D.
Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods.
- Trial name
- NCT02072148
- Testing
- PET/CT, Radiotherapy, Concurrent Chemoradiation
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.